Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
Phase 4
- Conditions
- Renal Insufficiency, ChronicCardiac CatheterizationPercutaneous Coronary Intervention
- Interventions
- Registration Number
- NCT05225077
- Lead Sponsor
- Dong-A University
- Brief Summary
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
- Age>18 years
- Written informed consent
- Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 [CKD stage G1-G3]
- Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients
Exclusion Criteria
- Active malignancy
- Class I or equivalent indication for treatment with a SGLT2 inhibitor
- Pregnancy or willing of pregnancy during the follow up period
- Active urogenital infection
- Diabetes mellitus type 1
- History of diabetic ketoacidosis
- Cardiogenic shock
- eGFR < 29 ml/min/1.73m2
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dapagliflozin 10mg group Dapagliflozin 10 MG [Farxiga] Dapagliflozin 10 mg once a day for 1 month after the procedure.
- Primary Outcome Measures
Name Time Method Incidence of contrast induced nephropathy 48 hours Serum creatinine (Scr) elevation of \>25% or \>0.5 mg/dl (44 μmol/l) from baseline within 48 hours
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Dong A University Hospital
🇰🇷Busan, Korea, Republic of